News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Alessandro Di Sanzo

Articles by Alessandro Di Sanzo

TIP134 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From ER+/HER2– Breast Cancer

ByNuhad Ibrahim, MD,Eva Ciruelos Gil,Sung-Bae Kim,Nancy U. Lin, MD,Ahmad Awada,Alessandro Di Sanzo,Bartomeu Piza Vallespir,Tomer Wasserman,Erika P. Hamilton, MD

May 4th 2026

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

ByNuhad Ibrahim, MD,Sung-Bae Kim,Nancy U. Lin, MD,Ahmad Awada,Eva Ciruelos Gil,Alessandro Di Sanzo,Bartomeu Piza Vallespir,Kathy Puyana Theall,Erika P. Hamilton, MD

August 3rd 2024

Latest Updated Articles

Trending on CancerNetwork

Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial

FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer

Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer

FDA Rejects Rivoceranib/Camrelizumab in First-Line Unresectable HCC

FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma